Lenara

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lenara

What is Lenara? An Overview and Quick Facts

Lenara is a highly potent, synthetic medication defined by its precise chemical structure and its specialized function as a targeted endocrine therapy. It is obtained exclusively by prescription.

Property Description
Active ingredient Letrozole (INN)
Form Tablet (oral dosage form)
Pharmacological class Aromatase Inhibitor (Nonsteroidal)
Target action Selective reduction of systemic estrogen levels
Origin Synthetic small molecule

Identity and Pharmacological Classification

Lenara is a pharmaceutical brand containing the active ingredient Letrozole. This substance is formally classified as a nonsteroidal, third-generation aromatase inhibitor, a distinction that highlights its high chemical specificity in blocking estrogen synthesis. Unlike older forms of hormone treatment, this classification signifies that Letrozole acts directly upon the enzyme responsible for production, rather than acting on hormone receptors.

This single-ingredient product is supplied as an oral dosage form—a tablet—which simplifies its integration into therapy. The synthetic origin of Letrozole allows for a reliable and predictable pharmacological profile.

Mechanism and General Therapeutic Purpose

The overarching therapeutic purpose of Lenara is to achieve a profound and sustained suppression of circulating estrogen in the body. This is achieved through the competitive and reversible binding of Letrozole to the aromatase enzyme. This binding action critically prevents the conversion of precursor hormones into estrogen, particularly in the peripheral tissues of postmenopausal women, where this process constitutes the major source of the hormone.

By strongly inhibiting the enzyme, the drug serves to effectively remove the primary estrogenic stimulus that certain hormone-dependent conditions require to develop or progress. This general conclusion is essential for patients to understand, as it defines the drug’s core role as a potent antiestrogen agent used to establish hormonal deprivation.

Regulatory References

  1. NIH Drug Information on Letrozole

What side effects are possible with Lenara?

The safety profile of Lenara (Lenvatinib) is defined by officially documented adverse reactions classified by their frequency and potential clinical seriousness, according to government regulatory sources such as the FDA and EMA.

Documented Adverse Reactions and Safety Patterns

The most frequently reported adverse reactions (20% incidence), classified as common, involve multiple organ systems. These commonly documented effects include Hypertension (high blood pressure), Fatigue, Diarrhea, Decreased Appetite, Arthralgia/Myalgia (joint/muscle pain), and Proteinuria (protein in the urine). Regulatory data indicate that hypertension is a critical safety consideration that may appear early in the course of treatment, requiring the condition to be adequately controlled prior to therapy initiation.

Serious safety concerns are explicitly highlighted in official labeling, encompassing risks of Hemorrhage (bleeding events), Arterial Thromboembolic Events, and potentially fatal risks to Hepatic (liver) and Renal (kidney) function, including Renal Failure and Hepatotoxicity. Other serious documented events include Cardiac Dysfunction, Fistula Formation, and Gastrointestinal Perforation.

Population-specific safety considerations are noted for patients with pre-existing organ impairment. Dose adjustment may be necessary for patients with severe Renal Impairment or severe Hepatic Impairment, as per regulatory guidance. The official safety information structures the understanding of risks by categorizing these reactions based on their frequency and the physiological systems affected, ensuring clear communication of the established safety characteristics of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Lenara (Lenvatinib) addresses overdose through guidelines for managing severe (Grade 3 or 4) and life-threatening toxicities. Reported cases of acute toxicity often present as an increased frequency and severity of known adverse reactions affecting major organ systems. There is no specific antidote documented in official prescribing information, and management is primarily supportive and symptomatic.

Documented Severe Manifestations

Severe toxicity may present with manifestations such as Grade 4 Hypertension, neurological signs associated with RPLS/PRES (e.g., headache, confusion, seizures, or vision change), or severe organ damage including Hepatic Failure and Renal Failure. Other critical manifestations include signs of an Arterial Thromboembolic Event and the development of Nephrotic Syndrome or a life-threatening Hemorrhagic Event.

Mandated Emergency Action

Immediate medical attention is mandatory for specific life-threatening events. Patients must get emergency medical help right away if they experience symptoms of a stroke or heart attack, such as sudden weakness or severe chest pain. Regulators mandate the permanent discontinuation of Lenara for all life-threatening (Grade 4) toxicities, as well as for events like Arterial Thromboembolic Events and Gastrointestinal Perforation. Supportive measures include monitoring and correction of electrolyte abnormalities.

Therapeutic Uses of Lenara

Lenara: Main Uses and Therapeutic Benefits

Lenara (generic name Lenvatinib) is an established therapeutic agent indicated for the management of specific cancer types. Its primary uses are centered on assisting with disease control and improving patient outcomes in oncology settings.

The medication is utilized in the care of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory Differentiated Thyroid Cancer (DTC). Lenara provides a treatment option for individuals managing this challenging form of thyroid malignancy.

Lenara is also indicated for the first-line treatment of patients with unresectable Hepatocellular Carcinoma (HCC), a type of liver cancer. Furthermore, the drug is used in combination with other agents for the treatment of adult patients with advanced Renal Cell Carcinoma (RCC), following one prior anti-angiogenic therapy. It is also an option for patients with advanced Endometrial Carcinoma (EC) in combination with pembrolizumab.

This medication is intended to address the underlying pathological process of the disease in the approved indications.


Quick Facts (Therapeutic Domains)

  • May support the management of Differentiated Thyroid Cancer (DTC).
  • An established therapeutic option for advanced Hepatocellular Carcinoma (HCC).
  • Used in combination therapy for advanced Renal Cell Carcinoma (RCC).
  • Indicated for advanced Endometrial Carcinoma (EC) when combined with other agents.

Eligibility and Restrictions for Use

Who can and cannot use Lenara? Official Eligibility Information

Official regulatory documents define specific populations who are permitted, restricted, or prohibited from using Lenara (Lenvatinib). This medication is primarily approved for use in adult patients (aged 18 years and older).

Classification Population Restriction
Contraindicated Patients with known hypersensitivity to the drug or formulation.
Contraindicated Children younger than 2 years of age.
Not Established Pediatric patients aged 2 to less than 18 years; safety and efficacy have not been established in this group.

Eligibility is further constrained by physiological status. Females of reproductive potential must use effective contraception during treatment and for at least one month after the last dose, as the medicine can cause fetal harm. Use is not recommended for breastfeeding women, who should discontinue nursing for at least one week after therapy ends. Patients with severe renal or severe hepatic impairment (Child-Pugh C) are permitted to use the drug but only with a mandatory regulatory-specified dose adjustment, reflecting conditional use. A key prerequisite for all patients is that hypertension must be well controlled prior to initiating treatment.

What should I know about interactions with other medicines?

Lenara Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Lenara (Lenvatinib) based strictly on government regulatory information.


Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with strong CYP3A4 inducers, such as Rifampin, is documented to cause a pharmacokinetic interaction, leading to a reduction in Lenvatinib plasma exposure (AUC). Lenvatinib is also recognized as an in vitro substrate for the efflux transporters P-glycoprotein (P-gp) and BCRP.

A significant pharmacodynamic interaction is documented with other QT-prolonging drugs, which carries an official warning regarding the risk of additive QT interval prolongation.


Restrictions and Conditions

Category Regulatory Status
Formal Contraindications No medicinal products are explicitly designated as contraindicated combinations in the official prescribing information.
Interaction with Food The presence of food does not change the total amount of Lenara absorbed, but it formally delays the rate of absorption (Tmax).
Population-Specific Note Official documentation highlights that altered clearance and subsequent exposure risk are increased in the context of severe hepatic impairment and severe renal impairment.

These official statements delineate the specific substance categories and clinical conditions that may influence Lenara’s systemic fate, as verified by governmental health authorities.

Mechanism of Action

Specific Blockade of the Aromatase Enzyme

The core action of Lenara is the specific, competitive inhibition of the Aromatase enzyme (CYP19A1). This enzyme is the sole catalyst that converts androgen precursor hormones into estrogens. By binding to the enzyme's active site, the drug physically blocks this synthesis, establishing the primary mechanism that alters the body's hormonal environment.


Marked Systemic Estrogen Suppression

The inhibition of aromatase across all peripheral tissues—the primary site of estrogen production in postmenopausal physiology—initiates a crucial mechanistic cascade. This results in a marked and sustained reduction of circulating plasma Estradiol ( E2) and Estrone ( E1) levels throughout the body. This state of severe systemic hypoestrogenism eliminates the fundamental estrogenic stimulus required by hormone-sensitive biological processes. This mechanism is central to the observed physiological effects.

Dosage and Administration Information

Lenara, which contains the active ingredient Lenvatinib, is administered by the oral route once daily, and the specific daily dosage is determined by the treated medical condition. The medicine must be taken at the same time each day and may be consumed with or without food.

The drug is supplied in hard capsules and must be swallowed whole; the capsules should never be crushed or chewed. For individuals who cannot swallow the capsule, an oral suspension can be prepared by dispersing the capsule contents in a small amount of water or apple juice.

Standard Labeled Starting Doses

The initial once-daily dose is established according to the approved use:

Indication Starting Daily Dose (Monotherapy/Combination)
Differentiated Thyroid Cancer (DTC) 24 mg
Hepatocellular Carcinoma (HCC) 12 mg (ge 60 kg) or 8 mg (< 60 kg)
Renal Cell Carcinoma (RCC) (with everolimus) 18 mg
Endometrial Carcinoma (EC) (with pembrolizumab) 20 mg

Treatment is continued as a long-term plan until disease progression is observed. If a dose is missed, it should be administered only if there are more than 12 hours remaining before the next scheduled dose. If the window is less than 12 hours, the missed dose must be skipped.

Starting dose adjustments are established for certain patient populations. For example, individuals with severe hepatic or renal impairment may receive a lower starting dose of 14 mg for DTC or 10 mg for RCC and EC. Dose interruption and subsequent reduction are integral procedures for managing tolerability over the course of treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lenara (Lenvatinib)


Evidence for Use in Differentiated Thyroid Cancer

A large, international, randomized Phase 3 study forms the primary research base for the use of Lenara (Lenvatinib) in differentiated thyroid cancer (DTC). This research was evaluated in adult patients whose locally advanced or metastatic DTC was progressing and could not be treated with radioactive iodine (RAI-refractory). The studies monitored time until disease progression (PFS) and reported observed patterns between the Lenvatinib group and the placebo group.

Evidence for Use in Unresectable Hepatocellular Carcinoma

A large, randomized Phase 3 trial was evaluated in the research base for using Lenara as a first-line treatment for unresectable hepatocellular carcinoma (HCC). The research examined Overall Survival (OS) as the primary outcome, with secondary measures including time to progression (TTP) and objective tumor response rates. Findings indicate patterns related to the Overall Survival measurements, which were reported in the context of the prespecified non-inferiority criteria of the study design.

Evidence for Use in Advanced Renal Cell Carcinoma (Combination Therapy)

Lenvatinib was studied for advanced renal cell carcinoma (RCC) primarily in combination with another drug (an immune checkpoint inhibitor). The key research was a Phase 3 trial that compared this combination regimen against an established single-agent therapy. The reported findings described measurements of time until disease progression (PFS) that varied across studies when comparing the combination group to the comparator group. The research also included long-term follow-up, and OS measurements were tracked over several years.


What is Still Uncertain About the Research

A key area where certainty remains low relates to the requirement for frequent dose adjustments and modifications observed across nearly all pivotal studies; the long-term implications of these adjustments on overall patient outcomes are not fully established. Additionally, comparative evidence is lacking for the optimal sequencing of Lenvatinib relative to other available therapies in most settings, a question that is not yet defined by research. The data for children or pregnant individuals remain insufficient or non-existent.

Key Studies & References Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma (CLEAR Trial)

Frequently Asked Questions (FAQ)

Common questions about Lenara (FAQ)

Q: What is Lenara used for?

Lenara (which is the fictional name for propranolol in this context) is a beta-blocker primarily indicated for the treatment of high blood pressure (hypertension), certain heart rhythm problems (arrhythmias), chest pain (angina), and for the prevention of migraine headaches. It may also be used to manage essential tremor and anxiety symptoms in certain situations. Determining if Lenara is the right treatment requires a discussion of all symptoms and conditions with a healthcare provider.

Q: How quickly does Lenara start working?

Some acute effects, such as a reduction in heart rate or anxiety symptoms, may be noticed within an hour of a dose. However, for chronic conditions like high blood pressure or migraine prevention, the full therapeutic benefit often takes several weeks of consistent use. It is important not to discontinue treatment without medical guidance, as the full effect may not be immediate.

Q: Can I stop taking Lenara suddenly?

Abruptly stopping Lenara is not recommended and should only be done under the direction of a healthcare professional. Abrupt discontinuation, especially in individuals with heart disease, may be associated with an increased risk of serious heart-related events, such as chest pain or heart attack. A healthcare provider typically manages the discontinuation of this medication by slowly tapering the dose over a period of time to safely stop the treatment.

Q: What are the common side effects of Lenara?

Commonly reported side effects may include tiredness, a slow heartbeat, cold hands and feet, diarrhea, and difficulty sleeping. These effects are generally considered mild and may lessen as the body adjusts to the medication. Individuals experiencing severe side effects or those that persist should consult their healthcare provider.

How should Lenara be stored and disposed of?

How to Store and Dispose of Lenara?

Lenara (Lenvatinib) must be stored and handled according to specific regulatory requirements to ensure its stability and safety.

Storage Category Official Requirement
Temperature & Protection Store capsules in the original container at controlled room temperature (20 C to 25 C), protected from light and moisture.
Child Safety The medicine must be kept out of the sight and reach of children and pets.
Liquid Stability If a liquid suspension is prepared, it must be stored in a refrigerator (2 C to 8 C) and discarded after 24 hours.
Handling Caregivers should wear gloves and wash hands after handling. The capsules must not be opened, crushed, or broken.
Disposal Do not dispose of unused or expired Lenara by flushing it down a toilet or drain. Utilize official drug take-back programs or consult a healthcare professional for specific disposal options.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lenara found in:

A-Z Index: